Ocugen Received Alignment From FDA On Key Aspects Of The Phase 3 Trial Design To Assess The Safety And Efficacy Of OCU400 In Patients With Rho And Other Gene Mutations Associated With Retinitis Pigmentosa
Ocugen Received Alignment From FDA On Key Aspects Of The Phase 3 Trial Design To Assess The Safety And Efficacy Of OCU400 In Patients With Rho And Other Gene Mutations Associated With Retinitis Pigmentosa
Ocugen 在 3 期試驗設計的關鍵方面獲得了 FDA 的同意，該試驗設計旨在評估 OCU400 在患有 Rho 和其他與色素性視網膜炎相關的基因突變患者中的安全性和有效性
Ocugen Received Alignment From FDA On Key Aspects Of The Phase 3 Trial Design To Assess The Safety And Efficacy Of OCU400 In Patients With Rho And Other Gene Mutations Associated With Retinitis Pigmentosa
Ocugen 在 3 期試驗設計的關鍵方面獲得了 FDA 的同意，該試驗設計旨在評估 OCU400 在患有 Rho 和其他與色素性視網膜炎相關的基因突變患者中的安全性和有效性